UNIONPAY
29.7.2020 10:02:43 CEST | Business Wire | Press release
UnionPay International, the card payment organisation with the world’s largest cardholder base, today announces a partnership with Glovo, the Barcelona-based on-demand economy technology start-up, which enables UnionPay cardholders to use its app initially in Spain, Portugal, France and Italy.
Founded in 2015, Glovo is an on-demand economy technology start-up that allows local stores to offer their products in the same city through the GLOVO App and supports intermediates in the delivery of such products. It is currently present in 22 countries including Croatia, France, Georgia, Italy, Poland, Portugal, Romania, Serbia, Spain and Ukraine.
This new partnership with Glovo enables UnionPay cardholders to make a wider range of purchases without the need to leave home. To encourage take up of the service while some lockdown measures are still in place, UnionPay customers have been offered free delivery until 15 August in Spain, Portugal and France.
UnionPay acceptance in France, Italy, Portugal and Spain has grown significantly in the last 12 months with a large number of online and offline merchants now accepting UnionPay cards. UnionPay’s cardholder base comprises Chinese ex-pats living and working in Europe, students from Asian countries, as well as a rapidly increasing domestic customer base among European nationals. This is particularly the case in Portugal where last year Millennium bcp became the first European bank to issue UnionPay cards.
Wei Zhihong, UnionPay International’s Market Director and Head of Europe said : “As one of the largest bankcard schemes worldwide, we are committed to providing payment ease for our cardholders. In this difficult time, we are making an extra effort, together with our partners, to offer safer and easier services to support our cardholders in Europe. We are very pleased to have reached a partnership with one of the world’s leading on-demand economy technology start-ups. Glovo is a company which has grown rapidly since its foundation in 2015 and through this new partnership the reach of its app is extended to our cardholders.
“With consumer behaviour changing as a result of COVID-19, more people are staying indoors and making purchases. This new partnership will enable our customers to benefit from Glovo’s platform and service, making purchases and arranging pick-ups without having to leave their own home. We are happy that we have been able to agree a delivery fee free period with Glovo to help keep costs down for cardholders. We look forward to announcing many more similar partnerships in the very near future.”
Sacha Michaud, Co-founder of Glovo said: “We are delighted to have reached a new partnership with UnionPay and hope that it represents the beginning of a long-term relationship which will benefit UnionPay card holders throughout France, Italy, Portugal and Spain. We look forward to working together on further partnerships as we move forward.”
With over 8.4 billion cards accumulatively issued worldwide, UnionPay is the card payment organisation with the world’s largest cardholder base. Its global network extends to 179 countries and regions, covering over 52 million merchants and more than 2.9 million ATMs worldwide.
- Ends -
About UnionPay International
UnionPay International (UPI) is a subsidiary of China UnionPay focused on the growth and support of UnionPay’s global business. In partnership with more than 2300 institutions worldwide, UnionPay
International has enabled card acceptance in 179 countries and regions with issuance in 61 countries and regions. UnionPay International provides high quality, cost effective and secure cross-border payment services to the world’s largest cardholder base and ensures convenient local services to a growing number of global UnionPay cardholders and merchants.
For more information, please visit: www.unionpayintl.com/en
For media enquiries please contact:
Citigate Dewe Rogerson
Oliver Parry/ Brandon Stockwell/ Patrick Evans
unionpay@citigatedewerogerson.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200729005031/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 13:33:00 CEST | Press release
Dr. Tracy Laabs named Director; Prof. Dr. Erwin Böttinger honored for his transformative leadership The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simult
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 13:24:00 CEST | Press release
Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk featuresNew European patient research reveals safety, disease severity, and effectiveness are the top drivers for first-line CLL treatment decisions – not time on therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D.,
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 13:00:00 CEST | Press release
Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib Safety profile was consistent with previous studies with no new safety signals identified Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrate
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 13:00:00 CEST | Press release
Transaction adds 31 CLOs and more than $5 billion of AUM, strengthening Clearlake Credit’s position in liquid credit Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 12:30:00 CEST | Press release
Partnership brings together LTTS’ expertise in its Sustainability segment and the Databricks platform to accelerate Engineering Intelligence across industrial operations. L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom